How to buy Kindred Biosciences stock

Kindred Biosciences is a drug manufacturers-specialty & generic business based in the US. Kindred Biosciences shares (KIN) are listed on the NASDAQ and all prices are listed in US Dollars. Kindred Biosciences employs 63 staff and has a trailing 12-month revenue of around $5.8 million.

Kindred Biosciences stock price (NASDAQ: KIN)

Use our graph to track the performance of KIN stocks over time.

Kindred Biosciences shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$4.83
52-week range	$0.00 - $0.00
50-day moving average more info button	$9.20
200-day moving average more info button	$6.64
Wall St. target price	$9.50
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-1.02

Buy Kindred Biosciences stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Kindred Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kindred Biosciences price performance over time

Historical closes compared with the close of $4.83 from 2021-05-28

1 week (2023-01-23)	N/A
1 month (2022-12-30)	N/A
3 months (2022-10-30)	N/A
6 months (2022-07-30)	N/A

1 year (2022-01-30)	N/A
2 years (2021-02-03)	-3.21%
3 years (2020-02-03)	8.94
5 years (2018-02-02)	8.45

Kindred Biosciences financials

Revenue TTM	$5.8 million
Gross profit TTM	$-1,162,000
Return on assets TTM	-23.11%
Return on equity TTM	-50.36%
Profit margin	0%
Book value	$1.76
Market capitalisation more info button	$420.5 million

TTM: trailing 12 months

Kindred Biosciences share dividends

We're not expecting Kindred Biosciences to pay a dividend over the next 12 months.

Kindred Biosciences share price volatility

Over the last 12 months, Kindred Biosciences's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kindred Biosciences's is 1.3152. This would suggest that Kindred Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kindred Biosciences overview

Kindred Biosciences, Inc. , a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California. As of August 27, 2021, Kindred Biosciences, Inc.

Frequently asked questions

What percentage of Kindred Biosciences is owned by insiders or institutions?
Currently 19.041% of Kindred Biosciences shares are held by insiders and 80.102% by institutions. How many people work for Kindred Biosciences?
Latest data suggests 63 work at Kindred Biosciences. When does the fiscal year end for Kindred Biosciences?
Kindred Biosciences's fiscal year ends in December. Where is Kindred Biosciences based?
Kindred Biosciences's address is: 1555 Bayshore Highway, Burlingame, CA, United States, 94010 What is Kindred Biosciences's ISIN number?
Kindred Biosciences's international securities identification number is: US4945771099 What is Kindred Biosciences's CUSIP number?
Kindred Biosciences's Committee on Uniform Securities Identification Procedures number is: 494577109